Panels - What Happens....

Quote
























These risks and uncertainties include, among others: whether Patent Application 12/823,007 will issue and, if issued, whether the validity and enforceability of the patent will be challenged by one or more third parties and upheld; whether preclinical and early clinical results for aripiprazole lauroxil will be predictive of future clinical study results; whether aripiprazole lauroxil will be shown to be ineffective or unsafe during clinical studies; decisions by the FDA or foreign regulatory authorities regarding aripiprazole lauroxil for the treatment of schizophrenia; potential changes in cost, scope and duration of the phase 3 clinical trial of aripiprazole lauroxil for the treatment of schizophrenia; and those risks described in the Alkermes plc Annual Report on Form 10-K for the year ended March 31, 2012, and in other filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available at the SEC’s website at www.sec.gov. The information contained in this press release is provided by the company as of the date hereof, and, except as required by law, the company disclaims any intention or responsibility for updating any forward-looking information contained in this press release.
 


















Alkermes Plc (NASDAQ:ALKS) CMO Elliot Ehrich sold 25,000 shares of the stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $62.39, for a total transaction of $1,559,750.00. Following the sale, the chief marketing officer now directly owns 24,956 shares in the company, valued at approximately $1,557,004.84. The sale was disclosed in a legal filing with the Securities & Exchange
 






CMO is a smart man - we all know the biotech companies are in a bubble that is part of a broader bubble in the NASDAQ (like 1999-2000) and the broader stock market in general.

Its a good idea to sell your stock into the all time highs and liquidate into cash. Only question is: When (not if) this bubble pops (it should happen VERY SOON as we are in the later "exponential vertical" phase of this mania) - who will be left standing when all the funding and liquidity dries up?
 


















whether Patent Application 12/823,007 will issue and, if issued, whether the validity and enforceability of the patent will be challenged by one or more third parties and upheld;


This statement says it all. This patent has been challenged. That is why no offers have been made and now several high up officials appear to be guilty of insider trading trading gross numbers of shares the DAY after the Abilify expected LOE when not ONE generic version was approved. The FDA's request to block Otsuka's request to block generic approvals doesn't seem to have moved the Federal Judge.

That guy had material information and sold a buttload of shares. He should go to white collar prison.

Tick tock.
 


















It's insider trading that they sold after Abilify LOE didn't happen on 4/20 and there is a case that may put it off for 7 years. If that happens, aripiprazole lauroxil may NOT see the light of day. Some big shots there know it and they are liquidating their assets before they plummet to worthless pieces of paper. It's obviously insider trading because someone briefed them on the chances of it being delayed for a significant period of time.
 






From what I can tell, No one had to "brief" anyone. The action Otsuka took against the FDA was public prior to 4.21. And anyone paying attention knows the purpose of the action, however, no one knows how it's going to play out. Nothing "insider" or "illegal" about his sell off, but a concern for anyone waiting call backs on these Lauroxil jobs and to anyone holding Alkermes stock. May be a good time to buy :)
 












Top Bottom
Back
Quote